Does Wegovy reduce visceral fat, and how much difference does it make?

What exactly is visceral fat, and why does losing it matter more than the number on the scales?

Most people picture body fat as the layer you can pinch. Visceral fat is different, it sits deep inside the abdominal cavity, packed between organs like the liver, pancreas and intestines. It is metabolically active in a way that subcutaneous fat is not: it releases inflammatory signals, contributes to insulin resistance and is independently linked to type 2 diabetes, cardiovascular disease and fatty liver disease, even in people whose total weight looks unremarkable.

There is a common assumption that any weight-loss treatment just shrinks the whole body uniformly. The evidence for semaglutide tells a more interesting story. Visceral fat appears to fall at a disproportionately high rate relative to total mass lost. That is clinically significant: the health risks associated with carrying excess weight are more closely tied to where fat sits than to the aggregate figure.

This is part of why researchers now pay close attention to visceral fat measurements in weight-management trials, rather than body weight alone. If you want to understand whether Wegovy helps with visceral fat and what the clinical evidence actually shows, our dedicated page works through both the mechanism and the trial data. For a broader overview of semaglutide as a medicine, the NHS semaglutide page is a reliable starting point.

How does Wegovy actually bring about reductions in visceral fat specifically?

Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist, it mimics the gut hormone GLP-1, which is released after eating. Activating these receptors slows how quickly the stomach empties, signals the brain to reduce appetite and improves the way the body handles blood glucose. The result is a sustained calorie deficit that feels less punishing than willpower-based dieting, because hunger itself is dampened.

Visceral fat responds to an energy deficit partly because it is more metabolically responsive than subcutaneous fat, it turns over faster and, under conditions of calorie restriction combined with improved insulin sensitivity, the body tends to draw on it early. Semaglutide's effect on insulin resistance may amplify this: lower circulating insulin levels reduce the signal to store fat in the abdominal depot.

The percentage reduction in visceral fat seen across STEP sub-studies has ranged considerably depending on measurement method and population, but the direction of effect is consistent. It is worth noting that trial participants also followed a reduced-calorie diet and increased their activity, semaglutide works alongside lifestyle changes, not instead of them.

Does Wegovy reduce belly fat you can see, or only the deep fat you cannot?

Both, in practice, though the proportions differ. Subcutaneous abdominal fat (the kind you can feel) does reduce with semaglutide treatment, and most people who lose a clinically meaningful amount of weight notice a visible change in their waistline. If you are curious about whether Wegovy reduces belly fat in the more visible sense and how that sits alongside the deeper visceral changes, our explainer on that question looks at both sides of the evidence.

The honest caveat is that individuals vary considerably. Someone carrying a large visceral fat burden at the start of treatment may see dramatic internal change before the mirror reflects much difference. Conversely, someone who loses weight predominantly from subcutaneous stores first may notice aesthetic changes sooner. There is no reliable way to predict distribution without imaging. Our page examining whether Wegovy gets rid of visceral fat explores the subcutaneous versus visceral distinction further if you want to go deeper on that question.

If you are thinking about what treatment might look like for you, our free consultation connects you with a GPhC-registered prescriber who can look at your specific situation. For context on what treatment costs privately, the Wegovy cost page sets out what the market looks like and what is typically included in a legitimate price.

Who is likely to see the greatest visceral fat reduction on Wegovy?

Trials enrolled adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as hypertension, raised cholesterol or sleep apnoea. These are also the groups where visceral fat is most likely to be a significant contributor to health risk, so the populations with the most to gain from visceral fat reduction are broadly the same ones the medicine is licensed to treat.

People with type 2 diabetes or pre-diabetes tend to carry more visceral fat relative to total body weight, and there is good evidence from the STEP programme that metabolic markers (HbA1c, triglycerides, blood pressure) improve alongside weight loss, consistent with a meaningful visceral fat effect. The NICE appraisal of semaglutide (TA875) focuses on the weight-loss indication and the conditions associated with excess weight, rather than visceral fat per se, but the comorbidities it names track closely with visceral adiposity.

Longer treatment duration, consistent adherence and combining semaglutide with genuine dietary changes and activity all tend to produce greater reductions. A prescriber assessing your case through our clinical team at nume will consider your health history and starting point, not just a single number. Check your eligibility by starting a free consultation at /pages/weight-loss-treatments.